Tuesday, 16 Jul 2019

You are here

Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women

It is estimated that 50% of women over the age of 50 will experience a facture related to osteoporosis. And while there are many effective therapies to lower this risk, the optimal duration of treatment is the subject of current debate.

The Journal of the American Geriatric Society has reported that older women receiving bisphosphonate therapy for greater than 10-13 years were more likely to suffer from fractures. ( Citation source: http://buff.ly/2qL1yQK)

In a subset observational study from the Womens Health Initiative, 5,120 older women who received bisphosphonates for greater than 2 years were assessed at different time intervals based on years of bisphosphonate use (2 years, 3–5, 6–9, 10–13 years). Fracture risk was calculated using 2 years as the referent group.

The length of time on bisphosphonates varied, with 13% takng bisphosphonates for 2 years,  34% for 3-5 years, 20% for 6-9 years, and 33% for 10-13 years.

The aveage age was 80 years and there were a total of 1313 fractures:127 hip, 159 wrist/forearm, and 235 vertebral fractures.

With 10-to-13 years of bisphosphonate use a 29% higher risk of any and all fractures was seen compared to 2 years of use (HR = 1.29, 95%CI; 1.07–1.57).  However, this was not statistically significant for hip (HR = 1.66, 95% CI = 0.81–3.40), clinical vertebral (HR = 1.65, 95% CI = 0.99–2.76), or wrist fracture (HR = 1.16, 95% CI = 0.67–2.00).

In older women at high risk of fracture, it appears that prolonged use (10-to-13 years) of bisphosphonate use was associated with higher risk of any clinical fracture compared to shorter periods (2 years) of use.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Safety Concerns Offset the Modest Improvements of Tanezumab in Osteoarthritis

JAMA reports that although tanezumab is modestly effective in moderate to severe osteoarthritis (knee or hip), with statistically significant improvements in pain and physical function, the tanezumab (TNZ) treated patients had more joint safety events and total joint replacements than patients treated with placebo.

Benefits vs Harms for Osteoporosis Drug Continuation or Discontinuation

While it is clear that long-term bisphosphonate therapies reduce fracture risk in women with osteoporosis, it is unclear how to counter-balance these benefits against rare serious harms and how to optimize therapeutic benefits with appropriate drug holidays. A systematic analysis of 48 studies compared long-term osteoporosis drug treatment (ODT) (>3 years) versus control versus ODT continuation versus durg discontinuation, to examine incident fractures or harms.

Mortality from Falls in the Elderly

JAMA reports that there is a trend of increasing mortality from falls in older US adults between 2000 to 2016 and that mortality rates are increased with increasing age. 

Knee Injuries Increases Osteoarthritis Risk

A systematic review of the medical literature shows anterior cruciate ligament (ACL), meniscus or combined ACL and meniscus injury significantly increases the risk of future knee osteoarthritis (OA).

The metanalysis comprised 53 studies and nearly 1 million participants, including 185,219 with ACL injury (mean age 28 years), 83,267 with meniscal injury (mean 38 years) and 725,362 with combined injury (mean 31 years).

Additive Effects of Insomnia and Depression on Osteoarthritis

A study of osteoarthritis patients, finds that pain is the primary driver for health care utilization, and that the presence of insomnia or depression augments health care use.

 A total of 2976 OA patients were followed for 3 years and assessed for pain (Graded Chronic Pain Scale), insomnia (Insomnia Severity Index), and depression (Patient Health Questionnaire‐8), and health care use (from electronic health records).